Search Results
Feb 21, 2026, 18:05 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory
More news about: THE ROSEN LAW FIRM, P. A.
Feb 20, 2026, 09:51 ET INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Faruqi & Faruqi, LLP
Feb 20, 2026, 04:27 ET Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO
INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of INO during the class period listed are encouraged
More news about: DJS Law Group LLP
Feb 20, 2026, 02:21 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
INO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Feb 19, 2026, 19:29 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
accelerated approval and/or priority review for the Biologics License Application ("BLA") of INO-3107 for the treatment of RRP (the "INO-3107 BLA"). Defendants also touted their ability to complete rolling submission of the INO-3107 BLA by the second half of 2024. In so doing, Defendants consistently and repeatedly
More news about: Pomerantz LLP
Feb 19, 2026, 09:15 ET Class Action Filed Against Inovio Pharmaceuticals, Inc. (INO) - April 7, 2026 Deadline to Join - Contact The Gross Law Firm
unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: The Gross Law Firm
Feb 18, 2026, 09:00 ET Class Action Filed Against Inovio Pharmaceuticals, Inc. (INO) - April 7, 2026 Deadline to Join - Contact Levi & Korsinsky
unlikely to submit it's lead product candidate, INO-3107 BLA to the FDA by the second half of 2024; (iii) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (iv) accordingly, INO-3107's overall regulatory and commercial prospects
More news about: Levi & Korsinsky, LLP
Feb 17, 2026, 02:25 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory
More news about: THE ROSEN LAW FIRM, P. A.
Feb 12, 2026, 16:02 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
accelerated approval and/or priority review for the Biologics License Application ("BLA") of INO-3107 for the treatment of RRP (the "INO-3107 BLA"). Defendants also touted their ability to complete rolling submission of the INO-3107 BLA by the second half of 2024. In so doing, Defendants consistently and repeatedly
More news about: Pomerantz LLP
Feb 12, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific and Investor Conferences
Wednesday, February 18Time: 7:30-10 PM PT, Poster Session APoster Presentation: Treatment of RRP with DNA immunotherapy INO-3107 induces activation and enrichment of pro-inflammatory CD4+ T cell responses in blood and airways of patients with clinical responseOppenheimer
More news about: INOVIO Pharmaceuticals, Inc.
Feb 11, 2026, 09:22 ET INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026
accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory and commercial prospects were
More news about: Faruqi & Faruqi, LLP
Feb 10, 2026, 20:36 ET IINO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Inovio Pharmaceuticals, Inc.
Pharmaceuticals, Inc. (INO) Misled Investors Regarding Approval for its CELLECTRA DeviceAccording to the complaint, during the class period, defendant failed to disclose that: (i) manufacturing for Inovio's CELLECTRA device was deficient; (ii) accordingly, Inovio was unlikely to submit the INO-3107 BLA to
More news about: Robbins LLP
Feb 10, 2026, 18:02 ET INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
submit the INO-3107 Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107's overall regulatory
More news about: THE ROSEN LAW FIRM, P. A.
Jan 15, 2026, 10:00 ET *CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,
More news about: Pomerantz LLP
Jan 14, 2026, 17:39 ET Greenberg Traurig Attorneys, Practices Recognized in The Legal 500 Asia Pacific 2026 Edition
Yuko Ino — Real estate and construction: International firms and joint ventures, Japan
More news about: Greenberg Traurig, LLP
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,
More news about: Pomerantz LLP
Dec 29, 2025, 08:05 ET FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
anticipated to allow INO-3107 to maintain T cell response and overall efficacy, which could make it an important therapeutic option for a majority of RRP patients.The FDA has granted INO-3107 both Orphan Drug and Breakthrough Therapy designations. The European Commission granted INO-3107 Orphan Drug
More news about: INOVIO Pharmaceuticals, Inc.
Dec 19, 2025, 16:05 ET INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa., Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer,
More news about: INOVIO Pharmaceuticals, Inc.
Nov 18, 2025, 09:00 ET QUEL Imaging and INO Announce Technology Transfer to Advance Biomedical Optics
About INO Canada's largest center of expertise in optics and photonics, INO creates and develops custom solutions to meet the needs of Quebec and Canadian companies in a wide range of industries. A leader in high technology, INO has implemented over
More news about: QUEL Imaging
Nov 11, 2025, 08:40 ET INOVIO Announces Pricing of $25 Million Public Offering
PLYMOUTH MEETING, Pa., Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer,
More news about: INOVIO Pharmaceuticals, Inc.
Nov 10, 2025, 18:09 ET INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa., Nov. 10, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer,
More news about: INOVIO Pharmaceuticals, Inc.
Nov 10, 2025, 17:31 ET Oropharyngeal Cancer Market to Register Steady CAGR Throughout Forecast Period (2025-2034) Amid Shifting Treatment Paradigms | DelveInsight
Inovio Pharmaceuticals and MedImmune's INO-3112 is a DNA-based therapeutic candidate targeting HPV types 16 and 18, paired with a plasmid encoding IL-12 to enhance immune activation. INOVIO is studying INO-3112's ability to generate antigen-specific T cells and promote their
More news about: DelveInsight Business Research, LLP
Nov 10, 2025, 16:05 ET INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
"I'm very pleased to report that we've completed the rolling submission of our BLA for lead candidate INO-3107. We believe every patient deserves a treatment that reduces exposure to surgery and INO-3107 has the potential to meet that significant need in the RRP community. The majority of patients in
More news about: INOVIO Pharmaceuticals, Inc.
Nov 06, 2025, 02:11 ET Kanazawa University research: Protein droplets in the nucleus guard against cancer
Yasuhiro Tsukamoto, Atsuki Kawamura, Ayhan Yurtsever, Hidefumi Suzuki, Nichole Marcela Rojas-Chaverra, Hiroki Sato, Daisuke Ino, Takehiko Ichikawa, Weilin Wei, Shojiro Haji, Dominic Chih-Cheng Voon, Akinobu Matsumoto, Kunio Matsumoto, Hidehisa Takahashi, Noriyuki Kodera, Takeshi
More news about: Kanazawa University
Nov 03, 2025, 08:05 ET INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
on the promise of INO-3107, an innovative DNA immunotherapy candidate that has the potential to become a paradigm-shifting treatment option for RRP," said Dr. Michael Sumner, Chief Medical Officer of INOVIO. "I'd like to thank the patients and physicians who participated in the INO-3107 clinical trial,
More news about: INOVIO Pharmaceuticals, Inc.